AU2013386732B2 - Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof - Google Patents

Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof Download PDF

Info

Publication number
AU2013386732B2
AU2013386732B2 AU2013386732A AU2013386732A AU2013386732B2 AU 2013386732 B2 AU2013386732 B2 AU 2013386732B2 AU 2013386732 A AU2013386732 A AU 2013386732A AU 2013386732 A AU2013386732 A AU 2013386732A AU 2013386732 B2 AU2013386732 B2 AU 2013386732B2
Authority
AU
Australia
Prior art keywords
compound
formula
substituent
carbon atoms
ethylpyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013386732A
Other languages
English (en)
Other versions
AU2013386732A1 (en
Inventor
Renle Hu
Yaqi Jiao
Jiucheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xian Libang Pharmaceutical Technology Co Ltd
Original Assignee
Xian Libang Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xian Libang Pharmaceutical Technology Co Ltd filed Critical Xian Libang Pharmaceutical Technology Co Ltd
Publication of AU2013386732A1 publication Critical patent/AU2013386732A1/en
Application granted granted Critical
Publication of AU2013386732B2 publication Critical patent/AU2013386732B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013386732A 2013-04-18 2013-04-18 Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof Ceased AU2013386732B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/074363 WO2014169462A1 (zh) 2013-04-18 2013-04-18 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法

Publications (2)

Publication Number Publication Date
AU2013386732A1 AU2013386732A1 (en) 2015-09-24
AU2013386732B2 true AU2013386732B2 (en) 2018-10-18

Family

ID=51730699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013386732A Ceased AU2013386732B2 (en) 2013-04-18 2013-04-18 Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof

Country Status (8)

Country Link
US (1) US20160060288A1 (https=)
EP (1) EP2987799B1 (https=)
JP (1) JP6356218B2 (https=)
KR (1) KR102046415B1 (https=)
CN (1) CN104936971B (https=)
AU (1) AU2013386732B2 (https=)
CA (1) CA2909418A1 (https=)
WO (1) WO2014169462A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169456A1 (zh) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
EP4061376A4 (en) * 2019-11-24 2024-03-13 Kashiv Biosciences, LLC Prodrugs of fulvestrant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218743A1 (de) * 1992-06-04 1993-12-09 Schering Ag Verfahren zur Herstellung C(7)-substituierter Estra-1,3,5(10)-triene sowie neue Ausgangsprodukte für dieses Verfahren
WO2005105823A1 (fr) * 2004-04-28 2005-11-10 Jiangsu Hansen Pharmaceutical Co., Ltd. Derives steroidiens
US20060030552A1 (en) * 2004-07-27 2006-02-09 Macdonald Peter L Process for the preparation of 7alpha-alkylated 19-norsteroids

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7613248A (nl) * 1976-11-26 1978-05-30 Akzo Nv Werkwijze voor het bereiden van nieuwe steroid- esters.
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5183514A (en) 1991-04-01 1993-02-02 Texaco Chemical Company Process for dissolving or removing rigid polyurethane foam by contacting with 1,2-dimethyl imidazole
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP2005524630A (ja) * 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
JP5256042B2 (ja) * 2005-11-22 2013-08-07 インサイト・コーポレイション 癌の処置のための併用療法
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
WO2014169456A1 (zh) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
US9271990B2 (en) * 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218743A1 (de) * 1992-06-04 1993-12-09 Schering Ag Verfahren zur Herstellung C(7)-substituierter Estra-1,3,5(10)-triene sowie neue Ausgangsprodukte für dieses Verfahren
WO2005105823A1 (fr) * 2004-04-28 2005-11-10 Jiangsu Hansen Pharmaceutical Co., Ltd. Derives steroidiens
US20060030552A1 (en) * 2004-07-27 2006-02-09 Macdonald Peter L Process for the preparation of 7alpha-alkylated 19-norsteroids

Also Published As

Publication number Publication date
US20160060288A1 (en) 2016-03-03
EP2987799A4 (en) 2016-10-05
CN104936971B (zh) 2017-10-13
KR20150143842A (ko) 2015-12-23
CA2909418A1 (en) 2014-10-23
EP2987799B1 (en) 2020-04-08
EP2987799A1 (en) 2016-02-24
KR102046415B1 (ko) 2019-12-02
WO2014169462A1 (zh) 2014-10-23
CN104936971A (zh) 2015-09-23
JP2016517849A (ja) 2016-06-20
AU2013386732A1 (en) 2015-09-24
JP6356218B2 (ja) 2018-07-11

Similar Documents

Publication Publication Date Title
WO2011014661A2 (en) Liver x receptor agonists
US9321804B2 (en) Synthesis and use of anti-tumor drug LQC-Y
CN112703003B (zh) 孕烷神经类固醇的脂质前药及其用途
WO2023207102A1 (en) Lipid nanoparticles
KR20220149534A (ko) 신경스테로이드의 지질 전구약물
CN103665087A (zh) 一种萜类化合物及其在医药上的应用
CN106061990A (zh) 一种阿比特龙衍生物及其制备方法和医药用途
AU2013386732B2 (en) Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
AU2016415408B2 (en) Rotigotine behenate, and preparation method and use thereof
CN121443581A (zh) 用于肌肉特异性递送的可电离脂质
CN106432141B (zh) 卡巴他赛药物前体的制备方法和应用
WO1995010527A1 (en) 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
KR20240056728A (ko) 치료제를 국소적으로 전달하기 위한 약물 전달 시스템 및 이의 용도
EP2987492B1 (en) Use of 7-a-[9-(4,4,5,5,5 - pentafluoro-pentyl-sulfinyl)nonyl]-estra-1,3,5(10)-triene-3,17b-diol and derivatives thereof
WO2023103929A1 (zh) 氟维司群衍生物及其制备方法和医药用途
CN111518157B (zh) 一种雷公藤甲素衍生物及其制备方法和应用
CN104151388A (zh) 抗肿瘤药物lqc-y的制备及其应用
RU2554475C2 (ru) ИММУНОМОДУЛИРУЮЩЕЕ СРЕДСТВО НА ОСНОВЕ 3-О-ПРОПИОНАТА АЛЛОБЕТУЛЕНОЛА (19β,28-ЭПОКСИ-18α-ОЛЕАНАН-3β-ИЛ И ПРОПИОНАТ)
KR20220164216A (ko) 신규한 에르고스텐올 유도체 및 이의 용도
JPH03133987A (ja) ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
HK40084022A (en) Lipid prodrugs of neurosteroids
CN103204897B (zh) 3,12位修饰的蜀羊泉碱衍生物、其制备方法、制剂及其医药用途
CN119798356A (zh) 一种紫杉醇分子伞递送系统前药及其制备方法和应用
CN114644673A (zh) 一种雌二醇衍生物、其制备方法及其在医药上的用途
Zeini et al. SQUALENOYLATED NANOPARTICLE PRODRUGS

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired